- Home
- BX vs REVBW Comparison
BX vs REVBW Comparison
Compare BX & REVBW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BX
- REVBW
- Stock Information
- Founded
- BX 1985
- REVBW N/A
- Country
- BX United States
- REVBW United States
- Employees
- BX N/A
- REVBW 9
- Industry
- BX Investment Managers
- REVBW Biotechnology: Pharmaceutical Preparations
- Sector
- BX Finance
- REVBW Health Care
- Exchange
- BX Nasdaq
- REVBW Nasdaq
- Market Cap
- BX N/A
- REVBW N/A
- IPO Year
- BX 2007
- REVBW 2020
- Fundamental
- Price
- BX $169.59
- REVBW $0.01
- Analyst Decision
- BX Buy
- REVBW
- Analyst Count
- BX 21
- REVBW 0
- Target Price
- BX $136.37
- REVBW N/A
- AVG Volume (30 Days)
- BX 3.0M
- REVBW N/A
- Earning Date
- BX 10-17-2024
- REVBW N/A
- Dividend Yield
- BX 1.93%
- REVBW N/A
- EPS Growth
- BX 22.69
- REVBW N/A
- EPS
- BX 2.91
- REVBW N/A
- Revenue
- BX $11,088,464,000.00
- REVBW N/A
- Revenue This Year
- BX $58.51
- REVBW N/A
- Revenue Next Year
- BX $23.91
- REVBW N/A
- P/E Ratio
- BX $58.36
- REVBW N/A
- Revenue Growth
- BX 34.51
- REVBW N/A
- 52 Week Low
- BX $88.59
- REVBW N/A
- 52 Week High
- BX $172.25
- REVBW N/A
- Technical
- Relative Strength Index (RSI)
- BX 77.88
- REVBW N/A
- Support Level
- BX $146.97
- REVBW N/A
- Resistance Level
- BX $153.55
- REVBW N/A
- Average True Range (ATR)
- BX 3.28
- REVBW 0.00
- MACD
- BX 0.96
- REVBW 0.00
- Stochastic Oscillator
- BX 89.48
- REVBW 0.00
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).